Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-012705
Filing Date
2022-03-16
Accepted
2022-03-16 07:31:04
Documents
4
Period of Report
2022-03-16

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea156904-6k_nlspharma.htm 6-K 11413
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES POSITIVE INTERIM TOP-LINE DAT ea156904ex99-1_nlspharma.htm EX-99.1 27121
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3404
4 GRAPHIC ex99-1_002.jpg GRAPHIC 14878
  Complete submission text file 0001213900-22-012705.txt   64979
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 22743293
SIC: 2834 Pharmaceutical Preparations